DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1970)

Sarcoidosis | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Sarcoidosis | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Coming Soon – June 2019


Sarcoidosis is an inflammatory disease of unclear etiology. It is characterized by tissue infiltration of granulomas, most commonly into the lung and lymph nodes, but the skin, heart, eyes, liver, and other tissues may also be affected. Although many sarcoidosis patients have nonprogressive disease or experience remission without treatment, more-severe disease can lead to organ damage (e.g., lung fibrosis) and necessitate pharmacotherapy, often with oral glucocorticoids. Although a modest evidence base drives use of conventional oral immunosuppressants and TNF-alpha inhibitors in the management of sarcoidosis, approved treatment options are greatly needed for patients who do not respond to, or are poor candidates for, oral corticosteroids.


  • What patient share do key therapies and brands garner by line of therapy in newly diagnosed sarcoidosis patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed sarcoidosis patients?
  • How have prednisone, oral immunosuppressants, and TNF-alpha inhibitors been integrated into the treatment algorithm, and what is their source of business?
  • What proportion of sarcoidosis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of sarcoidosis patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients with sarcoidosis?


Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Table of contents

  • Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
    • Coming Soon
      • Coming Soon

Already a Client? Log in to access this report.

  • Pub Date: February 2019
  • Author(s): John Crowley
  • John Crowley, ,  is an analyst in the CNS disorders group at Decision Resources. Prior to joining the company, Dr. Crowley was a postdoctoral associate at Harvard Medical School, where he studied mechanisms regulating the strength and dynamics of synaptic connections. He earned a from the University of Massachusetts Medical School, where he conducted research on the modulation of ion channel function by membrane lipids, and a from Worcester Polytechnic Institute.

Purchase Report

Recent reports:
You may also be interested in: